CITY OF HOPE NATIONAL MEDICAL CTR
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $908.2M
- Transactions
- 17,212
- Companies
- 40
- Average per transaction
- $52,767
Who reported the payments
| Genentech, Inc. | $609,805,502 |
| Merck | $43,133,645 |
| Amgen | $26,576,699 |
| AstraZeneca | $20,606,189 |
| Janssen Research & Development, LLC | $20,157,827 |
| Pfizer | $19,861,941 |
| AbbVie | $19,755,346 |
| Seagen Inc. | $17,736,859 |
| Bristol Myers Squibb | $16,929,609 |
| E.r. Squibb & Sons, L.L.C. | $7,904,650 |
| Kyowa Kirin, Inc. | $7,291,949 |
| Sanofi US Services Inc. | $6,901,363 |
| Exelixis Inc. | $6,874,149 |
| CSL Behring | $6,664,076 |
| Incyte Corporation | $6,274,708 |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,035,280 |
| Daiichi Sankyo Inc. | $3,795,473 |
| Servier Bioinnovation | $3,400,091 |
| Bayer | $3,152,795 |
| Jazz Pharmaceuticals Inc. | $2,912,014 |
| Astrazeneca UK Limited | $2,794,844 |
| Novartis | $2,509,675 |
| Beigene, Ltd. | $2,407,335 |
| Eli Lilly | $2,051,475 |
| Gilead | $1,959,478 |
| National Marrow Donor Program | $1,792,229 |
| Regeneron | $1,585,088 |
| Ipsen Biopharmaceuticals, Inc | $1,552,686 |
| Macrogenics, Inc. | $1,495,160 |
| Genmab U.S., Inc. | $1,363,115 |
| Karyopharm Therapeutics Inc. | $1,339,167 |
| Servier Pharmaceuticals LLC | $1,301,819 |
| Roche Products Limited | $1,260,833 |
| Coherus Oncology, Inc. | $1,247,258 |
| Taiho Oncology, Inc. | $1,146,911 |
| Genmab A/s | $1,116,778 |
| F. Hoffmann-la Roche AG | $1,116,520 |
| Pharmacyclics LLC, An Abbvie Company | $1,054,704 |
| Boehringer Ingelheim | $992,876 |
| Eisai Inc. | $977,310 |